エボラウイルスワクチンの世界市場機会分析

◆英語タイトル:MarketVIEW: Ebola virus vaccines - Global vaccine commercial opportunity assessment
◆商品コード:MR-VAMV061
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2015年4月
◆ページ数:82(PDFの場合)
◆レポート形式:英語 / PDF or Excel
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Executive Presentation (PDF)GBP3,000 ⇒換算¥468,000見積依頼/購入/質問フォーム
Forecast Model (Excel)GBP3,000 ⇒換算¥468,000見積依頼/購入/質問フォーム
PDF+ExcelGBP6,000 ⇒換算¥936,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、エボラウイルスワクチンの世界市場機会について調査・分析し、エボラウイルス感染症の概要、疫学トレンド、リスク要因、エボラウイルス感染症の診断、治療戦略、研究開発動向、ワクチン接種へのアプローチ、ワクチン開発における重要要素、ターゲット製品プロファイル、商用化/市場予測モデリング・シナリオ、価格分析、エボラウイルスワクチンの市場規模予測結果(金額及びボリューム)などの情報をお届けいたします。
【レポートの概要】

Ebola virus is a member of the Filoviridae family, which can cause a zoonotic disease in humans. The virus can be transmitted between humans via contact with infected body fluids or large droplets of infected fluids, causing a sudden disease with flu-like symptoms, digestive disorders and hemorrhaging. The mean case fatality of historical outbreaks is around 65%. Most Ebola outbreaks occur in central Africa, although latest outbreak is focused on West Africa with around 25,000 cases and over 10,000 deaths (March 2015). It is estimated that the West African region will lose between $3.6 and $4.9 billion in GDP per year for the next 3 years (UNDP figures).

A number of manufacturers are investigating Ebola vaccines in clinical studies. Major companies involved include Okairos/NIAID (GSK), Newlink/PHAC/Merck & Co, Johnson & Johnson. The most advanced in cAd3-EBOZ in Phase II/III Okairos/NIAID (GSK). A number of small molecules, gene silencing technologies and monoclonal antibodies are also being investigated.

This MarketVIEW product contains a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Ebola vaccines across relevant African countries until 2030. The model contains value ($ m) and volume (mio doses) predictions per vaccine type /per LO/BASE/HIGH scenarios along with timeframe, pricing and penetration estimates for all target populations/stockpile maintenance. The product also includes an in depth review of latest Ebola epidemiological trends, treatments/guidelines and latest developments in R&D.

*** THIS PRODUCT IS A EXECUTIVE PRESENTATION + 1 MODEL

【レポートの目次】

※レポート紹介PDF⇒ http://www.vaczine-analytics.com/VAMV061_TOC_150401.pdf

****This product is composed of two forecast models and a summary presentation
Author’s note
Contents
Executive Summary
Commercial model: key model outputs
Ebola vaccines: global forecast revenue per scenario ($m) to 2030
Ebola vaccines: global forecast revenue ($m), excluding high scenario to 2030
Ebola vaccines: global forecast volume per scenario (m) to 2030
Ebola vaccines: global forecast volume (m), excluding high scenario to 2030
Ebola vaccines: low scenario volume and value to 2030
Ebola vaccines: base scenario volume and value to 2030
Ebola vaccines: high scenario volume and value to 2030
Ebola vaccines: volume by vaccine type to 2030
Ebola vaccines: volume by country – low and base scenarios to 2030
Ebola vaccines: Infant immunisation volume by country (high scenario) to 2030
Ebola vaccines: adult catch-up programme volume by country (high scenario) to 2030
Ebola: disease background and epidemiology
Ebola: the pathogen
Ebola transmission to humans
Ebola transmission between humans
Pathogenesis of Ebola
Clinical presentation of Ebola
Common symptoms, signs and laboratory abnormalities associated with Ebola disease
Mortality and morbidity from Ebola (excluding 2014/15 outbreak)
Diagnosis of Ebola
Diagnosis of Ebola: WHO virus case classification categories
Management of Ebola: treatment and infection control
Ebola: prevalence and incidence worldwide
Ebola: at-risk groups
Focus on 2014/15 West African outbreak: background and disease dynamics
Origins and spread of the 2014/15 outbreak
Factors contributing to the rapid spread and impeded containment of the outbreak
Cumulative cases and deaths over time
Weekly cases: total
Weekly cases: by country
Geographical location of new and total confirmed cases
Spread over time: deaths
Status of the 2014/15 outbreak: March 2015
Nigeria, Senegal, Mali: successful containment avoids extensive outbreaks
Lessons to be learnt for the future
Economic and socioeconomic impact of 2014/15 outbreak
Management of Ebola: treatment and infection control
Personal protective measures for healthcare workers
Supportive management of Ebola cases
Infection control
Therapeutics against Ebola: experimental drugs
Development of therapeutics against Ebola
Small molecules in development for Ebola disease
Gene silencing technologies
ZMapp (Mapp Biopharmaceutical and LeafBio)
Ebola vaccines in development: overview of current R&D
History of Ebola vaccine development
Prospects for the future development of Ebola vaccines
Chimpanzee adenovirus 3-vectored vaccine (cAd3-EBOZ; GSK)
cAd3-EBOZ – phase I and phase II/III studies
VSV G-ZEBOV (rVSV-ZEBOV; Public Health Agency of Canada, NewLink, Merck & Co)
Other Ebola vaccines in development: Ad26.ZEBOV/MVA-BN-Filo (Johnson & Johnson)
PREVAIL: phase II/III study in Liberia with cAd3-EBOZ and rVSV-ZEBOV
Other Phase II/III studies ongoing in West Africa
Vaccination strategies aimed at the current epidemic
Ebola vaccines: immunisation strategies
Factors influencing vaccination strategy decisions
Vaccination strategies for prevention and control of future disease options
Considerations regarding vaccine coverage and efficacy
Ebola vaccine: ideal target product profiles (TPPs)
Ebola vaccines: modelling the current market
Scenarios to be modelled
Countries to be modelled
Vaccine assumptions
Modelling methodology: low scenario
Modelling methodology: base scenario
Modelling methodology: high scenario
Bibliography
About VacZine Analytics
Disclaimer

*** PAGES: ~82 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

[Contents – Vaccine demand model TX vaccine (MS Excel-based)]
Title sheet
CHARTS – summary
CHARTS – Lo/base/high
CHARTS – volume per vaccine type
CHARTS – volume per country
Summary volume and value.
Low scenario.
Base scenario.
Hi scenario
High risk infants =>
Guinea
Liberia’s 26th of May 20
Sierra Leone
DRC
Congo
Gabon
South Sudan
Uganda
Medium risk infants =>
Benin + Burkina Faso
Cameroon + Ghana
Guinea-Bis + Mali
Mauritania + Nigeria
Senegal + Gambia
Togo + Burundi
CAR + Cote D’Ivoire
Kenya + Sudan
Ethiopia + Rwanda
Tanzania + Zambia
Angol + Eq Guinea
Adult Catch-ups =>
Guinea + Liberia
Sierra Leone + Gabon
DRC + Congo
South Sudan + Uganda
Senegal + Guinea-Bissau
Mali + Cote D’Ivoire
Cameroon + CAR
Eq Guinea + The Gambia
Mauritania + Burkina Faso
Ghana + Kenya
Zambia + Angola
Togo + Benin
Nigeria + Sudan
Ethiopia + Rwanda
Burundi + Tanzania
Source data
Birth cohorts
High birth cohort
Infant mortality
Adults 15 yrs
YFV coverage (WHO)
Back page

*** Worksheets ~ 55 interconnected

【レポートのキーワード】

エボラウイルス、ワクチン、治療薬

【リサーチ方法】

VacZine Analytics has closely monitored all significant source material pertaining to Ebola virus, current and past outbreaks. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by VacZine Analytics in the field of novel vaccines has also been utilised.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ エボラウイルスワクチンの世界市場機会分析(MarketVIEW: Ebola virus vaccines - Global vaccine commercial opportunity assessment)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆